Extractables and Leachables Testing in the Pharmaceutical Industry

| July 27, 2017

article image
Leachables are organic or inorganic compounds that migrate into the drug product formulation from the container closure system as result of direct contact with the formulation. They are typically low‐molecular weight volatile compounds that migrate through semi‐permeable containers. Leachables testing is required for monitoring and controlling container closure‐ derived impurities in the drug product during stability and/or to qualify container closures for use. Potential sources of leachables include the container fabrication components, migrants from labeling or secondary packaging, and reaction products between the formulation and the container closure system. Leachables can present difficult analytical challenges, as they are frequently present at levels that are orders of magnitude lower than drug degradation products or related substances, well below the sensitivity of the Drug Product testing methods. Therefore, separate analytical methods are usually needed for leachable analysis on the drug product containers.

Spotlight

DRG Abacus

DRG Abacus, a Decision Resources Group company formally known as Abacus International, specialises in health outcomes; economic modelling, HTA, medical writing and market access services. Our client base includes the global and local affiliates of many of the leading pharmaceutical and devic.

OTHER ARTICLES

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

How pharma can continue engaging HCPs in a world gripped by COVID-19

Article | April 10, 2020

Medscape is the leading source of clinical news, health information, and point-of-care tools for healthcare professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programmes for physicians, nurses, and other healthcare professionals. Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company. Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Spotlight

DRG Abacus

DRG Abacus, a Decision Resources Group company formally known as Abacus International, specialises in health outcomes; economic modelling, HTA, medical writing and market access services. Our client base includes the global and local affiliates of many of the leading pharmaceutical and devic.

Events